Kornimate/medical-research-clean huggingface dataset:
clinical study on the effect of probiotic compound powder on the immunity improvement of preschool children

Conditions: Immunity

Summary: this is a randomized controlled trial, to evaluate the effect of wonderlab probiotic compound powder on improving immunity of preschool children

the community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group. first entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%.

Eligibility criteria:
inclusion criteria: * preschool children, male or female, 5 to 6 years old; * those with weak constitution and easy to get sick: one of them can be satisfied: aget cold ≥ 3 times a year b bronchitis or pneumonia ≥2 times per year c rotavirus diarrhea ≥1 time per year * during the trial, participants agree not to take any drugs, supplements, or other dairy products containing probiotics; * during the trial, participants agree not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt drinks; * willing to refrain from participating in other interventional clinical studies during the trial period; * be able to fully understand the nature, purpose, benefits and possible risks and side effects of the research; * willing to obey all test requirements and procedures; * informed consent signed by parents or legal guardians. exclusion criteria: * subject who is in the treatment of gastrointestinal diseases; * subject who has lactose intolerance; * the subjects are currently suffering from other organic diseases that affect intestinal function, such as history of gastrointestinal resection, colonic or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, hirschsprung's disease, scleroderma, anorexia nervosa, etc.; * subjects have any of the following medical histories or clinically diagnosed diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases; * according to the judgment of the researchers, frequent use of drugs that may affect gastrointestinal function or the immune system; * subjects who took laxatives or other digestive aids 2 weeks before the start of the study; * consumed dairy products or other foods containing prebiotics/bacteria within 10 days before the start of the study; * pi believes that volunteers cannot fully cooperate with the trial arrangement.

Keywords: rotavirus upper respiratory tract infection bristol scoring method
body parameters as an independent predictor of acute pancreatitis

Conditions: Acute Pancreatitis

Summary: this study is to assess the predictive significance of visceral adipose tissue (vat) and visceral adipose tissue /skeletal muscle tissue ratio (vat/smt ratio) for the prognosis in acute pancreatitis (ap) patients.

acute pancreatitis (ap) is a sudden inflammation of the pancreas. however, one-fifth of patients may develop severe complications with a mortality between 10%-20% it remains a difficulty to find an effective method for prediction of severity of ap at early stage. it is well-established that obesity (defined as body mass index\[bmi\]\>30kg/m2 by the world health organization) is a risk factor for ap and increases the incidence of systemic complication, motality. there are a lot of parameters related to saropenic obesity, including areas of visceral adipose tissue (vat), subcutaneous adipose tissue (sat), skeletal muscle tissue (smt), and vat/smt ratio. it is unclear which parameter is the best predictor of severe ap. thus, this study is aimed to investigate the association between these parameters and ap severity and find the best predictor of ap.

Eligibility criteria:
inclusion criteria: 1. diagnosed with ap 2. age \>18 years exclusion criteria: 1. age\<18years 2. missing data in the electronic medical record 3. history of ap
midazolam efficacy/safety in pre-eclamptic c-section sedation

Conditions: Midazolam; Pre-eclampsia; Cesarean Section; Efficacy; Safety

Summary: this study will compare four different doses of midazolam (0 mg/kg, 0.01 mg/kg, 0.02 mg/kg, and 0.03 mg/kg) administered intravenously to women with pre-eclampsia undergoing cesarean section. the study aims to evaluate how these different doses affect: the mother's vital signs (oxygen levels, blood pressure, heart rate) the mother's anxiety levels the baby's condition after birth any potential side effects participants will be randomly assigned to one of the four dose groups. medical staff will monitor both mother and baby for 24 hours after the medication is given.

this study aimed to investigate the efficacy and safety of different doses of midazolam for 24-hour continuous sedation in pre-eclamptic women undergoing cesarean section. a total of 124 pre-eclamptic women admitted from april 2021 to april 2023, scheduled for cesarean section at our hospital, were randomly assigned to group a, group b, group c, and group d, with 31 women in each group. midazolam was administered intravenously at doses of 0 mg/kg, 0.01 mg/kg, 0.02 mg/kg, and 0.03 mg/kg, respectively. we compared the oxygen saturation (spo2), mean arterial pressure (map), and heart rate (hr) levels before and 30 minutes after drug administration in all four groups. visual anxiety scores, fetal kreb's scores, and sedation efficacy indicators (fentanyl dosage, onset time of sedation, mechanical ventilation time) were assessed in the women at 24 hours before and after the surgery. adverse reactions were also recorded.

Eligibility criteria:
inclusion criteria: * pregnant women diagnosed with pre-eclampsia \[6\] requiring emergency or planned cesarean section * age 18-40 years * no history of midazolam or related drug allergies * able to comply with study protocol (no communication barriers) * no history of mental illness or substance abuse * provided informed consent (patient or legal representative) exclusion criteria: * concurrent use of drugs interacting with midazolam * severe organ dysfunction (heart, liver, or kidneys) * participation in other clinical trials potentially affecting results * coagulation disorders or hematological conditions * inability to adhere to study protocol * severe intraoperative complications (e.g., hemorrhage) compromising data reliability * additional sedative/analgesic use within 24 hours post-cesarean
n-of-1 trials using mhealth in chronic pain

Conditions: Musculoskeletal Pain; Chronic Pain

Summary: chronic musculoskeletal pain is an important problem, and treatments are often prescribed in a "trial and error" fashion. clinicians prescribe a treatment to a patient and then wait and see if the treatment is successful. if the treatment is unsuccessful, they will try a different treatment. the disadvantage to this method is that it may take a long time to find a successful treatment. the purpose of the preempt study is to test whether using a mobile phone application ("trialist app") that allows patients and their health care providers to run personalized experiments comparing two pain treatments is more effective than usual care. patients download the app, and working with their clinicians, set up a personalized trial that makes sense for them. every day they answer questions to track levels of pain and side effects of treatment, such as fatigue and constipation. once the personalized trial has ended, the responses to these daily questions on each treatment will be compared. during a regular clinic visit, the patient and the clinician will review visual displays of the results to facilitate treatment decision-making. approximately 250 patients will be enrolled in the study. half the patients will use the app and review results with the clinician, and half the patients will continue with their regular care (i.e., will not use the app). the two groups will be compared to see if using the app is successful in improving long term pain outcomes. the goal of the intervention using the trialist app is to help patients engage actively and collaboratively with their clinicians and identify effective treatments more quickly.


Eligibility criteria:
inclusion criteria: * chronic musculoskeletal pain (e.g., neck, back, extremities) operationalized as pain present for 6 weeks or more and a pain score of 4 or higher (on a 0-to-10 scale) on at least one of three items from the peg pain scale * age 18-75 years * own web-enabled android or ios phone with data plan * in judgment of treating clinician, pain potentially amenable to treatment with acetaminophen, nonsteroidal anti-inflammatory drugs (nsaids), low-dose opioids, a complementary/alternative treatment such as massage or meditation, or a simple combination of these treatments * ability to speak and read english exclusion criteria: * treated with surgery, radiation or chemotherapy for cancer in past 5 years * other medical conditions that in clinician's judgment would limit life expectancy to less than 2 years or imperil patient safety * pregnant or breastfeeding * dementia, bipolar disorder, schizophrenia, active suicidality * current alcohol or prescription drug abuse; history of disruptive behavior * failed 5 or more analgesic medications because of lack of effectiveness or poor tolerability

Keywords: musculoskeletal pain chronic pain patient centered outcomes research physician patient relationship mobile applications
morbidity and mortality after esophageal and esophagogastric junction cancer surgery

Conditions: Esophageal Cancer; Oesophageal Cancer; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type III Adenocarcinoma of Esophagogastric Junction

Summary: esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure. however, esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively there is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the russian federation.

esophageal and esophago-gastric junction cancer is the seventh most common malignancy and the sixth leading cause of cancer-related mortality worldwide. surgery remains the primary treatment for esophageal cancer and is one of the most technically challenging interventions in oncological surgery. in addition, esophagectomy is associated with high risks of postoperative complications, with rates varying from clinic to clinic. esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively. the problem with the available studies of the course of the postoperative period is the significant heterogeneity of research methods, which does not allow us to obtain a true picture of the results of surgical treatment of the esophagus and esophagogastric junction cancer in the russian federation. to improve the quality of further studies and recommendations on standardization of surgical treatment of esophageal and esophagogastric junction cancer and its morbidity, there is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the russian federation.

Eligibility criteria:
inclusion criteria: * all consecutive patients with clinically documented primary esophageal or esophagogastric junction malignancy (including siewert i and ii) undergoing elective surgery with curative intent - via open, laparoscopic or robotic approach between 18th march 2024 and 18th september 2024 exclusion criteria: * patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers. * esophagogastric junction siewert iii malignancy * patients submitted to emergency surgery or surgery without curative intent * patients undergoing any other surgery in addition to the curative surgery for primary esophageal or esophagogastric junction malignancy

Keywords: esophageal cancer esophagogastric junction cancer morbidity mortality surgery
plasty or prosthesis to treat functional mitral regurgitation

Conditions: Functional Mitral Regurgitation

Summary: functional mitral regurgitation is a now well known entity due to tethering of the valve either mono-lateral, as happens in lateral myocardial infarction, or bilateral as happens in dilated cardiomyopathy. treatment of this pathology, either conserving the valve and addressing regurgitation by mean of restrictive annuloplasty, or implanting a prosthesis remains controversial in terms of mid and long term benefit for the patient. the investigators propose a randomized controlled study to compare the efficacy of both technique in terms of mortality and freedom from reintervention.


Eligibility criteria:
inclusion criteria: * all patients presenting for surgery due to functional mitral regurgitation exclusion criteria: * associated heart surgery procedures other than cabg, tricuspid regurgitation correction, atrial fibrillation correction

Keywords: functional mitral regurgitation
investigating the sleeping habits of patients with haemophilia

Conditions: Sleep Disorder; Psychological; Activity, Motor

Summary: this investigation aims to explore sleeping habits in patients with haemophilia. these patients often suffer from joint pain, which leads to restricted physical activity. further, many of the patients suffer from psychological strains, such as depression. both depression and restricted physical activity can result in sleeping disorders. thus it is aimed to find out which factors and comorbidities do play a role within sleeping habits in patients with haemophilia.


Eligibility criteria:
inclusion criteria: * adult (≥ 18 years) patients with haemophilia (all severities) or von-willebrand-disease (typ iii) * female carriers * signed informed consent exclusion criteria: * patients with other bleeding disorders * patients with acute injuries, psychological disorders or prior surgeries (in the last 6 weeks) * no signed informed consent
respiratory mechanics effects of flutter valve in bronchiectasis patients

Conditions: Bronchiectasis

Summary: considering that respiratory physiotherapy lack scientific evidence to support its application in the treatment of several obstructive diseases, this investigation was designed to evaluate the hypothesis that flutter valve can improve the airway clearance of hypersecretive bronchiectasis patients.

the application of airway clearance techniques is considered an important component in the treatment of bronchiectasis patients (van der shans, 1997). for this purpose, a number of techniques has been introduced in the last decades. the flutter valve was initially proposed for the treatment of children with cystic fibrosis (cf) (lindemann, 1992), but there is not enough evidence about its utilization in patients with bronchiectasis (van der shans \& cols, 1999). the effects of the flutter valve on respiratory mechanics of patients with bronchiectasis have been evaluated by forced spirometry (pryor e cols, 1994; gondor e cols, 1999; thompson e cols, 2002). this approach however, does not allow the characterization of mucus transportation along the airways (williams, 1994). the forced oscillation technique (fot), a non-invasive alternative to characterize respiratory mechanics, allows the evaluation of respiratory mechanics at different frequencies without special maneuvers (dubois e cols., 1956). according to eligibility criteria and in a randomized order, the patients were submitted to two protocols (control and flutter valve intervention), with one-week interval between them (washout). respiratory mechanics and expectorated sputum volume were assessed before and after each intervention, in order to assess the flutter valve effect on tracheobronchial sputum removal.

Eligibility criteria:
inclusion criteria: * patients with clinical and high-resolution computerized tomography diagnosis. exclusion criteria: * chest pain, * acute hemoptysis, * recent history of rib fracture or pneumothorax (less than 1 year), * respiratory infection in the four weeks before measurements, * asthma, * cystic fibrosis, * daily sputum production lower than 25 ml/day

Keywords: bronchiectasis physiotherapy flutter valve impulse oscillation technique
pulsed dye laser and intense pulsed light (ipl) for the treatment of telangiectasia and skin redness

Conditions: Telangiectasis; Erythema

Summary: the purpose of the study is to compare efficacy and adverse effects of pulsed dye laser and intense pulsed light in patients with skin telangiectasia and redness.


Eligibility criteria:
inclusion criteria: * 18 years or older * skin types i, ii, iii * no previous laser or ipl treatment for the condition exclusion criteria: * younger than 18 years old * skin types iv, v, or vi * pregnant or lactating women * previous laser or ipl treatment for the condition * recent exposure to sun or sun-beds * treatment with oral retinoid within 6 months * tendency to produce hypertrophic scars or keloids

Keywords: telangiectasia skin redness
the patency period of the new plastic anti-reflux biliary stent

Conditions: Pancreatitis; Cholangitis

Summary: the aim of this study is to determine the average patency period of the new anti-reflux biliary stent on patients with malignant bile duct strictures and to determine if this stent remains patent for a longer period of time comparing with the ordinary plastic tannenbaum biliary stent.

bile duct related cancer is a condition quite commonly seen among asians. predisposing conditions for primary bile duct cancer include recurrent infections and autoimmune diseases such as recurrent pyogenic cholangitis (rpc) and primary sclerosing cholangitis (psc) as well as congenital problem such as choledochal cyst. peri-ampullary tumour, pancreatic tumour and metastatic tumours with bile duct compression are other causes of bile duct obstruction. as many of these tumours are discovered at a late stage, curative treatment is usually not feasible. palliative endoscopic stenting of the obstructed biliary system remains the treatment of choice for the majority. the main problem with endoscopic stenting of the biliary system is the short stent patency period. there are some reports on modifications to plastic biliary stenting method in recent years including changes in stent designs, use of a different material or coating, administrating prophylactic antibiotics and the use of special drugs. all these have failed to show any conclusive effect on the stent patency period. a preliminary study has demonstrated some promising results in the use of a stent with an anti-reflux property very similar to the stents the investigators are using in this study.

Eligibility criteria:
inclusion criteria: * age 18 years old * patients who have cholangiographic evidence (on ercp) consistent with a malignant extrahepatic biliary stricture (below bifurcation of the common hepatic duct) who require plastic stenting * patients with peri-ampullary tumours, pancreatic tumours, gall bladder cancer and metastatic tumours with suspected extrinsic bile duct compression * patients with stent or nasobiliary drain in-situ without previous sphincterotomy will qualify for the study if they satisfy the above inclusion criteria. exclusion criteria: * patients fit for surgery. * patients who have dominant biliary strictures involving the hilum or more proximal biliary segments. * previous sphincterotomy. * other medical conditions that will result in a life expectancy of less then 3 months (asa class \>4) * pregnancy

Keywords: stent occlusion biliary bleeding biliary perforation
effects of pleural effusion drainage on respiratory system mechanics

Conditions: Pleural Effusion

Summary: the effects of pleural drainage on lung mechanics are unknown. insertion of esophageal balloon will allow us to measure and assess pleural pressure, and thus assess any possible effects of pleural fluid drainage may have on lung mechanics.

esophageal balloon will be inserted prior to pleural fluid drainage.

Eligibility criteria:
inclusion criteria: * mechanically ventilated patients with significant pleural fluid documented by ct scan or us.who are candidates for pleural fluid drainage. exclusion criteria: * patients with any of the following were excluded from the study. previous lung or chest wall surgery, previous esophageal surgery, known achalasia or any other esophageal motility or spasm disorder, presence of chest thoracostomy tube, and any significant chest wall abnormality such as kyphoskoliosis.

Keywords: lung compliance pleural effusion esophageal pressure
sodium-potassium blood pressure trial in children

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases

Summary: to examine the effects of nutritional intervention on the rate of rise of blood pressure in late childhood and early adolescence.

background: since 1970, children and adolescents with hypertension have been detected with increasing frequency. many of them were thought to have primary or essential hypertension and it remained unclear how they should be managed. additionally, since tracking of blood pressure occurred even in early life, it was believed that youngsters with blood pressures persistently in the upper deciles for age were at increased risk for later hypertension. no clinical trials had been performed in this age group to examine the effects of non-pharmacologic or drug therapy in lowering blood pressure. the trial was one of the first attempts to examine the effects of a nutritional intervention on the rate of rise of blood pressure in late childhood and early adolescence. design narrative: randomized, partial-blind. after 19,542 fifth to eighth grade students were screened, 210 (105 boys and 105 girls) from the upper 15 percentiles of blood pressure distribution were randomly assigned to one of three groups: low sodium diet (70 mmol sodium intake per day), potassium chloride supplementation (normal diet plus 1 mmol/kg potassium chloride per day), and placebo (normal diet plus placebo capsule). capsules for the potassium chloride and placebo groups were administered in a double blind protocol. blood pressure was measured every three months for three years. the effect of the intervention was determined by comparing the rate of rise (slope) of blood pressure among the groups using a random-coefficient growth curve model.

Eligibility criteria:
children in grades 5 through 8 whose systolic blood pressure was greater than or equal to 120 mm hg on two visits.